350 related articles for article (PubMed ID: 16763570)
1. A license to print money?
Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
[No Abstract] [Full Text] [Related]
2. Four rebuffs for Cabilly.
Waltz E
Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392001
[No Abstract] [Full Text] [Related]
3. India's IP snub.
Jayaraman KS
Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
[No Abstract] [Full Text] [Related]
4. Kenyan dispute illuminates bioprospecting difficulties.
Sheridan C
Nat Biotechnol; 2004 Nov; 22(11):1337. PubMed ID: 15529141
[No Abstract] [Full Text] [Related]
5. Indian biogenerics industry emerges.
Jayaraman KS
Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
[No Abstract] [Full Text] [Related]
6. Protecting rights to early-stage technology.
Shuster MJ; Su H; Blaug S
Nat Biotechnol; 2003 Jun; 21(6):701-3. PubMed ID: 12776151
[No Abstract] [Full Text] [Related]
7. Gene patents--a pharmaceutical perspective.
Tribble JL
Camb Q Healthc Ethics; 1998; 7(4):429-32. PubMed ID: 9752585
[No Abstract] [Full Text] [Related]
8. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
9. Patents: the public interest versus the private privilege.
Parsi KP; Egan EA
Am J Bioeth; 2002; 2(3):45-6. PubMed ID: 12230857
[No Abstract] [Full Text] [Related]
10. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
Silbermann JM
J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
[No Abstract] [Full Text] [Related]
11. Patentability issues surrounding antivirals.
Lu DL; Collison AM; Kowalski TJ
Nat Biotechnol; 2007 Dec; 25(12):1403-4. PubMed ID: 18066035
[No Abstract] [Full Text] [Related]
12. A nail in the coffin for DNA sequence patents?
Yamanaka M
Nat Biotechnol; 2008 Oct; 26(10):1085-6. PubMed ID: 18846072
[No Abstract] [Full Text] [Related]
13. Proposed changes to patent code loom over biotech industry.
Coombs A
Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
[No Abstract] [Full Text] [Related]
14. It is not unethical, though it is often unwise, to override patents.
Leventer H
Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
[No Abstract] [Full Text] [Related]
15. Recent Supreme Court decisions and licensing power.
Giordano-Coltart J; Calkins CW
Nat Biotechnol; 2008 Feb; 26(2):183-5. PubMed ID: 18259170
[TBL] [Abstract][Full Text] [Related]
16. Life, death, and monopoly rights in a democratic society.
Smith SJ
Am J Bioeth; 2002; 2(3):43-4. PubMed ID: 12230856
[No Abstract] [Full Text] [Related]
17. US courts narrow patent exemptions.
Fox JL
Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
[No Abstract] [Full Text] [Related]
18. The zinc finger nuclease monopoly.
Scott CT
Nat Biotechnol; 2005 Aug; 23(8):915-8. PubMed ID: 16082353
[No Abstract] [Full Text] [Related]
19. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
20. Cabilly patent finale.
Waltz E
Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
